Denali Therapeutics
$24.10
24H
Market Cap
Volume
Supply
Price Chart
About Denali Therapeutics - DNLI
Denali Therapeutics Inc. is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases such as Parkinson's, Alzheimer's, and ALS. They utilize a range of methods including proprietary drug delivery systems to target the brain and central nervous system.
What are Denali Therapeutics's core values and mission statement?
Denali Therapeutics Inc.'s mission is to defeat neurodegenerative diseases through rigorous therapeutic discovery and development. Their core values emphasize the importance of scientific excellence, collaboration, and a commitment to benefiting patients.
Who founded Denali Therapeutics and when?
Denali Therapeutics Inc. was founded by Ryan Watts, Alexander Schuth, and Marc Tessier-Lavigne in 2013.
Who leads Denali Therapeutics?
As of the last update, Ryan Watts was the CEO of Denali Therapeutics Inc.
Where is Denali Therapeutics located, and what is its base country?
Denali Therapeutics Inc. is headquartered in South San Francisco, California, and its base country is the United States.
On which exchanges is Denali Therapeutics traded?
Denali Therapeutics Inc. is traded on the NASDAQ Stock Market under the ticker symbol DNLI.
Historical data
Denali Therapeutics (DNLI) Price Live Data
The live price of Denali Therapeutics (DNLI) is $24.10, with a trading volume of 345,051 in the last 24 hours. Wrapstocks updates the DNLI price in real-time. Denali Therapeutics is up 0.04% in the last 24 hours. The company has a live market cap of $3,436,876,800.00 and a supply of 142,608,996 DNLI stocks.
Denali Therapeutics (DNLI) is traded on NASDAQ Stock Exchange, and currently, the market is closed; trading will be resumed in 7 hours and 58 minutes.
